Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 31Triple Negative Breast Neoplasms 19Neoplasm Metastasis 5Urinary Bladder Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Salivary Gland Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Mouth Neoplasms 1Meningeal Carcinomatosis 1Lung Diseases 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Etoposide 79Carboplatin 67Cisplatin 58durvalumab 29Irinotecan 29Radiotherapy 27atezolizumab 23Topotecan 21anlotinib 19Nivolumab 15Drug Therapy 15Radiosurgery 14Gemcitabine 13apatinib 12Paclitaxel 12toripalimab 10Platinum 10Docetaxel 10tislelizumab 9Temozolomide 9PM 01183 8pembrolizumab 7olaparib 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Bevacizumab 7Albumin-Bound Paclitaxel 7irinotecan sucrosofate 6Counseling 6sintilimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Carcinoma × sacituzumab govitecan × Clear all
NCT07339059 2026-04-23

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Henry Ford Health System

Phase 2 Recruiting
35 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡